Home
About
Overview
Sharing Data
ORCID
Help
History (28)
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping.
Osimertinib long-term tolerability in patients with EGFRm NSCLC enrolled in the AURA program or FLAURA study.
Afatinib in the treatment of squamous non-small cell lung cancer: a new frontier or an old mistake?
Phenotypic Plasticity and Cancer: A System Biology Perspective.
The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies.
See All 28 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies.
The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies. Future Oncol. 2024; 20(27):1983-1991.
View in:
PubMed
subject areas
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Clinical Trials as Topic
Humans
Neoplasms
authors with profiles
Marina Chiara Garassino